LeMaitre (LMAT) is an Incredible Growth Stock: 3 Reasons Why
LeMaitre (LMAT) possesses solid growth attributes, which could help it handily outperform the market.
LMAT - LeMaitre Vascular, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$127.50
DETAILS
HIGH:
$135.00
LOW:
$120.00
MEDIAN:
$127.50
CONSENSUS:
$127.50
UPSIDE:
30.43%
Stock News
LeMaitre to Participate at Upcoming Investor Conferences in June
BURLINGTON, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in two upcoming investor conferences in June.
Down 17.2% in 4 Weeks, Here's Why LeMaitre (LMAT) Looks Ripe for a Turnaround
LeMaitre (LMAT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
LeMaitre to Present at the Bank of America Healthcare Conference
BURLINGTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT) announced today that management will present at the Bank of America Healthcare Conference on Wednesday, May 13, 2026, at 5:15 PM PT.
3 Reasons Growth Investors Will Love LeMaitre (LMAT)
LeMaitre (LMAT) is well positioned to outperform the market, as it exhibits above-average growth in financials.
LeMaitre (LMAT) Upgraded to Buy: Here's Why
LeMaitre (LMAT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
LeMaitre Vascular, Inc. (LMAT) Q1 2026 Earnings Call Transcript
LeMaitre Vascular, Inc. (LMAT) Q1 2026 Earnings Call Transcript
LeMaitre Vascular (LMAT) Tops Q1 Earnings Estimates
LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $0.48 per share a year ago.
LeMaitre Q1 2026 Financial Results
BURLINGTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q1 2026 results, announced a quarterly dividend of $0.25/share, and provided guidance.
Comerica Bank Lowers Holdings in LeMaitre Vascular, Inc. $LMAT
Comerica Bank trimmed its position in LeMaitre Vascular, Inc. (NASDAQ: LMAT) by 6.7% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 133,243 shares of the medical instruments supplier's stock after selling 9,589 shares during the quarter. Comerica Bank owned 0.59% of
Q1 2026 In Review - March Dividend Income Report
After 3 months in 2026, I heard more noise than quality information. Therefore, I don't intend to make any modifications to my portfolio at this point. Dollarama reported a mixed quarter with revenue up 12%, but EPS was up only 2%. That sent the stock price down and created the temptation to invest a little more in this amazing company. I'm accumulating more dividends in this portfolio, and I'll shortly have another $1,000 to invest! I will likely add more of Broadcom as I'm not yet fully invested at 3% of the portfolio in this security.
LeMaitre Will Announce First Quarter 2026 Earnings Results on May 5, 2026
BURLINGTON, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its first quarter 2026 financial results on Tuesday, May 5, 2026, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook.
LeMaitre to Present at the 25th Annual Needham Virtual Healthcare Conference
BURLINGTON, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will present at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16, 2025, at 2:15 PM EDT.
LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives Consensus Rating of “Moderate Buy” from Brokerages
Shares of LeMaitre Vascular, Inc. (NASDAQ: LMAT - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seven research firms that are covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average
A LeMaitre Vascular (LMAT) Insider Sold 2,625 Shares for $285K
2,625 shares were exercised and sold on March 11, 2026, generating a transaction value of approximately $285,000 at a weighted average sale price of around $108.50 per share. This disposition represented 28.22% of Kamke's direct holdings prior to the transaction, reducing direct ownership to 6,677 shares.
LeMaitre Vascular Up 30% as Insider Sells $285K in Stock. Here's What Investors Should Know
An executive of LeMaitre Vascular reported selling 2,625 shares of the company for $285,000 on March 11, 2026. The sale represented 28.22% of Kamke's direct common stock holdings, reducing the position to 6,677 shares.
LeMaitre Vascular, Inc. $LMAT Shares Acquired by Congress Asset Management Co.
Congress Asset Management Co. boosted its stake in LeMaitre Vascular, Inc. (NASDAQ: LMAT) by 5.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 732,331 shares of the medical instruments supplier's stock after acquiring an additional 40,065 shares during the quarter. Congress Asset Management Co.
The Two Forces Reshaping Your Portfolio - February Dividend Income Report
The market has been going through a visible rotation. Dividend payers have been outperforming so far this year as investors rotate from large-cap AI names into “old economy” stocks. If you own software names that depend on pricing power through expensive licensing, you need to revisit your thesis. Higher energy prices would ultimately filter through to consumer and producer prices, leaving central banks scrambling to reassess their interest rate trajectory.
Dynamic Technology Lab Private Ltd Invests $477,000 in LeMaitre Vascular, Inc. $LMAT
Dynamic Technology Lab Private Ltd bought a new stake in shares of LeMaitre Vascular, Inc. (NASDAQ: LMAT) in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 5,450 shares of the medical instruments supplier's stock, valued at approximately $477,000. A number of
LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives $105.80 Average Target Price from Analysts
Shares of LeMaitre Vascular, Inc. (NASDAQ: LMAT - Get Free Report) have been assigned an average rating of "Hold" from the seven brokerages that are currently covering the firm, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average
Price Targets
LeMaitre price target raised to $135 from $110 at Lake Street
$135.00
(was $105.37)
Frank Takkinen
·
Lake Street
LeMaitre price target raised to $120 from $105 at Barrington
$120.00
(was $112.00)
Barrington
Cantor Fitzgerald Reiterates Neutral Rating on LeMaitre Vascular (LMAT)
$95.00
(was $86.96)
Ross Osborn
·
Cantor Fitzgerald
LeMaitre resumed with a Buy at Roth Capital
$108.00
(was $87.26)
Roth Capital
LeMaitre price target raised to $110 from $105 at Lake Street
$110.00
(was $91.85)
Lake Street
LeMaitre initiated with a Neutral at Cantor Fitzgerald
$96.00
(was $92.14)
Ross Osborn
·
Cantor Fitzgerald
LeMaitre price target raised to $100 from $77 at JMP Securities
$100.00
(was $85.53)
Daniel Stauder
·
JMP Securities
Stifel Upgrades LeMaitre Vascular (LMAT) to Buy
$75.00
(was $65.46)
Rick Wise
·
Stifel Nicolaus
Why LeMaitre Vascular Is A Market Leader In Core Segments: Oppenheimer Initiates With Outperform Rating
$70.00
(was $56.71)
Suraj Kalia
·
Oppenheimer